AV Medical Technologies Ltd. announced today the culmination of a 30 patient study that evaluated the proprietary design of the Chameleon™ angioplasty balloon catheter. The study was conducted by Dr. Anthony Verstandig, Director of Interventional Radiology at Shaare Zedek Medical Center in Jerusalem. Study results were presented during an oral abstract presentation at the recent Society of Interventional Radiology (SIR) conference held in Vancouver, Canada.
Discussing his Initial Clinical Experience with the Chameleon™ at SIR, Dr. Verstandig stated, “The Chameleon™ demonstrated clear advantages compared to standard balloon designs. Among these are reduced catheter exchanges and maintaining guidewire access during contrast injection through the catheter. In addition, the Chameleon™ design allows hands free reflux angiography, simplifying visualization of the entire AV graft circuit.”
Mrs. Limor Sandach, AV Medical’s CEO, commented, “We are very pleased with the results of this trial and we are excited to commence our US launch. The Chameleon™ balloon offers unique advantages over standard balloon catheters. We are confident that physicians will appreciate the benefits provided by our proprietary SuperVision™ feature.”
SuperVision™ is a proximal injection technology enabling simultaneous catheter based interventions and contrast fluid injection for imaging in one device, eliminating multiple exchanges and maintaining guidewire access. This proprietary technology enhances performance by achieving superior targeted imaging and a smoother and more efficient procedure.
About A-V Medical
AV Medical Technologies Ltd, a privately held medical device company headquartered in Israel, is dedicated to the development of advanced and efficient solutions in catheter-based interventions. The company is now focusing on its flagship catheter, the Chameleon™, targeted for dialysis patients undergoing routine angioplasty procedures. The company was founded by Dr. Michael Tal, interventional radiologist and serial entrepreneur.
